Physician profile
Carol Storey
NPI 1124096532
$3,717.96
in general payments reported to CMS, 2019-2025
33 companies · $41.59 in 2025
The $41.59 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $142 · 2021: $575 · 2022: $688 · 2023: $647 · 2024: $186 · 2025: $41.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $629.43 | 2019 | |
| Therapeuticsmd, INC. | $450.77 | 2019-2021 | |
| Pfizer INC. | $371.43 | 2019-2023 | |
| Abbvie INC. | $322.67 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $258.41 | 2021-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $208.98 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.88 | 2019-2023 | |
| Hologic Sales and Service, LLC | $143.59 | 2019-2024 | Aptima, Thinprep 2000 Processor, Novasure |
| Myovant Sciences INC. | $135.90 | 2021-2022 | |
| Medtronic, INC. | $127.47 | 2022-2023 | V-Loc 180, Closurefast |
| Ascend Therapeutics US, LLC | $110.47 | 2021 | |
| Sumitomo Pharma America, INC. | $104.61 | 2023-2025 | Myfembree |
| Pacira Pharmaceuticals Incorporated | $69.46 | 2021 | |
| Avion Pharmaceuticals | $60.24 | 2019-2022 | |
| Organon LLC | $54.47 | 2022-2024 | Nexplanon |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $52.92 | 2021-2023 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $52.78 | 2021 | |
| Amag Pharmaceuticals, INC. | $49.92 | 2019-2020 | |
| Millicent US INC | $44.41 | 2023 | Intrarosa, Femring |
| Mylan Pharmaceuticals INC. | $39.33 | 2019-2022 | |
| Evofem Biosciences, INC. | $34.28 | 2022 | |
| Applied Medical Resources Corporation | $33.51 | 2022 | |
| Allergan, INC. | $30.73 | 2019 | |
| Becton, Dickinson and Company | $27.18 | 2023 | Bd Max System, Bd Max Instrument |
| Innovation Technologies INC | $26.55 | 2024 | Irrisept |
| Renovia INC | $26.21 | 2019 | |
| Acessa Health INC. | $21.85 | 2019-2020 | |
| Covidien LP | $20.82 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.71 | 2019 | |
| Shield Therapeutics INC | $13.63 | 2022 | |
| Ibsa Pharma INC. | $13.11 | 2022 | |
| Minerva Surgical, INC | $11.13 | 2019 | |
| Lupin INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Storey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.